2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
46
Lung Neoplasms
19
Melanoma
18
Neoplasm Metastasis
16
Carcinoma, Hepatocellular
15
Neoplasms
13
Esophageal Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
10
Colorectal Neoplasms
9
Breast Neoplasms
9
Head and Neck Neoplasms
8
Stomach Neoplasms
6
Rectal Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Carcinoma, Renal Cell
6
Brain Neoplasms
6
Small Cell Lung Carcinoma
5
Recurrence
5
Pancreatic Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Multiple Myeloma
4
Liver Neoplasms
4
Glioblastoma
4
Cholangiocarcinoma
4
Prostatic Neoplasms
3
Nasopharyngeal Carcinoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Interventions
Cisplatin
6
pembrolizumab
5
fludarabine
5
Nivolumab
5
Cyclophosphamide
5
aldesleukin
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Ifosfamide
4
Radiotherapy
3
Ipilimumab
3
fludarabine phosphate
2
entinostat
2
cabozantinib
2
avelumab
2
aflibercept
2
Specimen Handling
2
CTLA-4 Antigen
2
Biopsy
2
Adoptive Transfer
2
vinflunine
1
toripalimab
1
rocakinogene sifuplasmid
1
ripretinib
1
oncogene protein E7, Human papillomavirus type 16
1
niraparib
1
nimotuzumab
1
lenvatinib
1
enfortumab vedotin
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Penile Neoplasms
×
Immunotherapy
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled